HHLR Advisors’s Cytokinetics CYTK Stock Holding History

HHLR Advisors’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-230,718	Closed	-$5.37M	–	90
2021 Q1	$5.37M	Hold	230,718	–	–	0.05%	76
2020 Q4	$4.79M	Buy	+230,718	New	+$4.22M	0.04%	86

Other funds holding CYTK

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

HHLR Advisors's CYTK Position: Q2 2021 in Review

HHLR Advisors sold out of Cytokinetics (CYTK) in Q2 2021, closing a stake of 230,718 shares — an estimated $5.37M sold.

HHLR Advisors first reported a position in CYTK in Q4 2020 and held it in 2 quarters. The position peaked at $5.37M in Q1 2021. 190 funds tracked by Wall St. Rank hold CYTK as of Q2 2021.

HHLR Advisors reported no remaining Cytokinetics position as of Q2 2021 after selling out during the quarter.
HHLR Advisors sold 230,718 Cytokinetics shares in Q2 2021, an estimated $5.37M.
HHLR Advisors first reported a position in Cytokinetics in Q4 2020 and held it in 2 quarters.
HHLR Advisors's Cytokinetics position peaked at $5.37M in Q1 2021.
190 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2021.

Based on HHLR Advisors's 13F filing for Q2 2021, filed 16 Aug 2021.